paper
publish
year
ago
journal
us
describ
potenti
therapeut
benefit
quinolin
antimalari
chloroquin
viral
diseas
sever
acut
respiratori
syndrom
sar
chloroquinehydroxychloroquin
sinc
adopt
treat
patient
clinic
trial
new
insight
antivir
activ
obtain
invitro
studi
hivaid
front
chloroquin
mg
twice
daili
administ
patient
baselin
viral
load
copi
per
ml
combin
lamivudin
mg
twice
daili
hydroxyurea
mg
twice
daili
ongo
clinic
trial
india
ten
volunt
undetect
viral
load
week
median
drop
viral
load
log
median
log
drop
seen
nucleosid
revers
transcriptas
inhibitor
nrti
hydroxyurea
alon
result
differ
anoth
trial
singapor
use
didanosin
mg
twice
daili
hydroxyurea
mg
twice
daili
hydroxychloroquin
mg
twice
daili
correspond
mg
chloroquin
median
drop
viral
load
log
similar
induc
nrti
plu
hydroxyurea
followup
patient
week
suggest
valu
hydroxychloroquin
may
lie
mainten
effect
didanosin
hydroxyurea
discrep
two
studi
besid
differ
design
patient
enrol
probabl
reflect
differ
dosag
chloroquinehydroxychloroquin
drop
viral
load
report
occur
use
daili
dose
mg
hydroxychloroquin
correspond
mg
chloroquin
use
indian
studi
use
mg
chloroquin
daili
correspond
mg
hydroxychloroquin
adopt
singapor
studi
chloroquinehydroxychloroquin
might
thu
valuabl
option
test
lowcost
antiretrovir
combin
correct
dosag
use
consid
studi
new
insight
antivir
effect
chloroquin
empir
activ
caus
filament
fungi
timetest
experi
newer
agent
may
use
microbiolog
diagnosi
establish
eg
voriconazol
aspergillu
spp
posaconazol
zygomycet
although
studi
requir
lastli
van
damm
hartman
refer
noma
chancrum
ori
devast
necrotis
destruct
process
face
typic
affect
young
malnourish
children
africa
condit
present
recent
excel
review
barattimay
colleagu
thank
van
damm
hartman
interest
paper
comment
allow
us
elabor
upon
import
topic
rapidli
progress
ssti
particip
regularli
monitor
prevent
retinopathi
prospect
randomis
doubleblind
placebo
studi
also
need
assess
contribut
chloroquinehydroxychloroquin
part
antiretrovir
regimen
accord
new
invitro
result
antiretrovir
effect
chloroquin
attribut
inhibit
viral
particl
glycosyl
effect
appear
specif
sinc
chloroquin
concentr
effect
vitro
neither
affect
step
replic
cytotox
hypothesi
chloroquin
might
inhibit
replic
sar
coronaviru
confirm
two
independ
invitro
studi
research
belgian
cathol
univers
leuven
found
chloroquin
inhibit
sar
coronaviru
replic
effect
concentr
se
moll
within
rang
blood
concentr
achiev
antimalari
treatment
dose
induc
cytostat
activ
much
higher
moll
timeofaddit
experi
indic
chloroquin
affect
earli
stage
sar
coronaviru
replic
research
center
diseas
control
prevent
atlanta
ga
usa
report
potent
antisar
coronaviru
effect
chloroquin
vitro
attribut
deficit
glycosyl
sar
coronaviru
receptor
antivir
drug
concentr
cytotox
anim
model
confirm
result
chloroquin
might
repres
valuabl
therapeut
option
sar
reemerg
broad
spectrum
antivir
effect
chloroquin
deserv
particular
attent
time
world
threaten
possibl
new
influenza
computerassist
simul
ligandprotein
dock
use
program
gold
indic
chloroquin
red
fit
activ
site
udpnacetylglucosamin
grey
evid
suggest
chloroquin
could
inhibit
enzym
catalys
ratedetermin
step
sialic
acid
biosynthet
pathway
pandem
avail
effect
drug
would
fundament
evalu
effect
vaccin
effect
chloroquin
replic
orthomyxovirida
long
known
inhibitori
effect
chloroquin
type
b
influenza
virus
describ
current
investig
inhibitori
effect
chloroquin
avian
influenza
viru
recent
isol
poultri
itali
depend
viral
challeng
dose
method
adopt
detect
antivir
effect
inhibitori
concentr
fell
within
moll
rangei
clinic
achiev
plasma
malaria
treatment
ldt
id
rc
ac
unpublish
data
effect
confirm
chloroquin
would
deserv
test
type
avian
influenza
viru
current
matter
seriou
concern
public
health
discuss
glycosyl
inhibit
might
repres
major
mechan
antivir
effect
chloroquin
suggest
specif
interact
chloroquin
sugarmodifi
enzym
glycosyltransferas
may
occur
within
human
cell
figur
chloroquin
recent
shown
inhibit
quinon
reductas
structur
neighbour
udpnacetylglucosamin
involv
sialic
acid
biosynthesi
chloroquin
inde
inhibit
biosynthesi
sialic
acid
effect
could
explain
effect
chloroquin
hiv
sar
coronaviru
sialic
acid
moieti
present
glycoprotein
sar
coronaviru
receptor
also
invitro
effect
orthomyxovirus
use
sialic
acid
moieti
receptor
effect
deserv
investig
may
lead
new
strategi
control
replic
sever
virus
start
infecti
diseas
fellowship
programm
year
ago
first
traine
andrew
kambugu
complet
train
last
septemb
recruit
faculti
member
idi
three
other
current
programm
primarili
use
american
model
includ
emphasi
develop
clinic
investig
expertis
current
mainli
focus
hivaid
traine
complet
train
intern
medicin
paediatr
mentor
member
allianc
director
also
made
experi
avail
north
america
train
microbiolog
manitoba
canada
western
clinic
infecti
diseas
salt
lake
citi
ut
usa
one
current
traine
paediatr
infecti
diseas
rotat
baylor
houston
tx
usa
anoth
tuberculosi
epidemiolog
rotat
atlanta
ga
usa
object
programm
train
african
infecti
diseas
academ
leader
tomorrow
part
commit
build
human
resourc
